Single-agent antitumor efficacy of a novel oral INV-25 Liver X receptor (LXR) agonist in a checkpoint-refractory mouse B16-F10 melanoma model for Oral Presentation at the 2018 AAD Meeting in San Diego

AAD San Diego 2018.JPG

Abstract entitled "Antitumor efficacy following oral INV-25 Liver X receptor (LXR) agonist monotherapy in the B16-F10 melanoma mouse model" to be presented as Oral Presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California February 16-20, 2018.

Read Here + 

Preclinical POC data in a mouse Psoriasis model following Topical treatment with small molecule INV-17 ROR gamma inhibitor presented at the 2017 EADV Annual Meeting in Geneva, Switzerland

EADV 2018 Geneva.png

Topical administration of INV-17 small molecule ROR gamma inhibitor clinical candidate compound following disease induction in a mouse imiquimod-induced psoriasis disease model demonstrates therapeutic efficacy.

Read Here +

Innovimmune awarded NIH NIAID SBIR Phase II $3 Million grant for the development of its proprietary oral INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors for Autoimmune Diseases

NIAID.png

Innovimmune is awarded a $3 million, three-year (2014-2017) National Institute of Health (NIH) Phase II SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAIAD) to advance the preclinical development of proprietary First-in-Class INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors for Rheumatoid Arthritis, its novel proprietary oral small molecule MIF inhibitor portfolio in development for the treatment of autoimmune and rare diseases.